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Abstract
Lysosomal storage diseases are a group of disorders where accumulation of catabolites is manifested in the
lysosomes of different cell types. In metachromatic leukodystrophy (Arylsulfatase A [EC.3.1.6.8] deficiency) storage of
the glycosphingolipid sulfatide in the brain leads to demyelination, resulting in neuromotor co-ordination deficits
and regression. In a mouse model for metachromatic leukodystrophy, the ASA null mutant mouse, the
accumulation of sulfatide in correlation to phenotype has been thoroughly investigated. Another lipid species
reported to accumulate in patients with metachromatic leukodystrophy is the sulfatide related lipid lysosulfatide.
Lysosulfatide was shown to be a cytotoxic compound in cell culture experiments and thus suggested to be
involved in the pathology of metachromatic leukodystrophy. In this study, we further investigated the
developmental profile of lysosulfatide in the brain of ASA null mutant mice by using high performance liquid
chromatography. Lysosulfatide could be detected in the brain of normal mice (ASA +/+) from 1.8 months up to
23.1 months of age. From the age of 8.8 months the lysosulfatide levels remained constant at 1 pmol/mg wet
tissue. The developmental change (< 20 months) of brain lysosulfatide showed an accumulation in ASA null
mutant mice at ages above one month compared to its normal counterpart (ASA +/+). Thus, the ASA null mutant
mouse might be a suitable model to further investigate the role of lysosulfatide in the pathogenesis of
metachromatic leukodystrophy.
Introduction
The hypothesis of lysosphingolipids being cytotoxic cata-
bolites in leukodystrophies was put forward in 1972 by
Miyatake and Suzuki [1]. They investigated globoid cell
leukodystrophy (Krabbe disease), caused by a deficiency of
galactosylceramidase, and found increased concentrations
of galactosylsphingosine (psychosine) in post-mortem
brain tissue. The accumulation of galactosylsphingosine in
the Krabbe brains was confirmed by Svennerholm et al.
who also structurally characterized the isolated compound
[2]. An accumulation of galactosylsphingosine was also
shown in the natural mouse model for Krabbe disease, the
twitcher mouse [3,4], and a close relationship between the
abnormal abundance of galactosylsphingosine and demye-
lination was suggested. In other lysosomal storage diseases
(LSDs), such as Gaucher disease, GM1 and GM2 ganglio-
sidoses, Niemann-Pick type A and Fabry disease, abnormal
accumulations of lysosphingolipids in various tissues have
also been shown [5-10].
Metachromatic leukodystrophy (MLD) is an autosomal
recessive inherited LSD (OMIM 250100) where the
enzyme arylsulfatase A (ASA, EC. 3.1.6.8) is deficient
[11]. Due to this enzyme deficiency, galactosylceramide-
3-O-sulfate (Sulfatide, Figure 1) accumulates within the
lysosomes of various tissues. Sulfatide is a major compo-
nent of the myelin sheet in the nervous system and
accumulation of sulfatide in oligodendrocytes of this
region leads to severe demyelination. However, sulfatide
is probably not responsible for the complete demyelina-
tion process since this compound is a natural non-toxic
component of brain myelin. Furthermore, the accumula-
tion of sulfatide does not accompany the demyelination
in some MLD patients [12].
Another lipid species reported to accumulate in
patients with MLD is lysosulfatide (the deacylated form
of sulfatide or sulfogalactosylsphingosine, Figure 1)
[13,14]. Lysosulfatide is considered to be a cytotoxic
substance in vitro, where 150 μM lysosulfatide showed a
50% inhibition of protein kinase C [15] and 50-100 μM
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more, lysosulfatide sulfatase is deficient in MLD fibro-
blasts [16]. Recent studies have also shown regulatory
functions of lysosulfatide using neuronal precursor cells,
where lysosulfatide inhibited cell migration via calcium-
mediated process collapse [17].
The ASA null mutant mouse model created by Hess
et al [18] was shown to have no ASA enzyme activity and
the pattern of lipid storage resembles that of the human
situation. The most severe form of MLD in humans (late
infantile), which is caused by a complete lack of ASA
activity, is associated with progressive demyelination,
neuromotor co-ordination deficits and regression. How-
ever, the ASA null mutant mice (no ASA activity) show
an attenuated phenotype compared with MLD patients
with no enzyme activity. The animals display demyelina-
tion of the peripheral nervous system, astrogliosis and
aberrant morphology of Bergmann glia and cerebellum
[19]. Furthermore, mice become deaf and show various
neuromotor abnormalities.
T h ea i mo ft h i ss t u d yw a st oi n v e s t i g a t et h eo c c u r -
rence and developmental profile of lysosulfatide in an
A S An u l lm u t a n tm o u s em o d e lb yu s i n gh i g hp e r f o r -
mance liquid chromatography (HPLC).
Materials and methods
Animals and animal tissues
Chimeric male mice obtained by injection of embryonic
stem cells with targeted disruption of the ASA gene into
blastocysts [18] were mated with C57BL/6J wildtype
females. The offspring were analyzed by Southern blot
analysis of tail DNA for the presence of the disrupted
ASA allele. Mice heterozygous for the knockout allele
(ASA +/-) were mated to obtain ASA-deficient (ASA
-/-) and wildtype control mice (ASA +/+). Animals were
bred under standard conditions and all experimental
protocols were performed with due permission from the
appropriate local and national authorities.
For lipid analyses, mice were anaesthetized with CO2
and killed by cervical dislocation. The brains were dis-
sected out (the cerebellum and medulla oblongata were
removed), immediately frozen in liquid nitrogen and
stored at -80°C. ASA -/- mice were examined at 1.1, 4.2,
9.2, 15.6, 18.5 and 20.6 months of age with 2-4 animals
in each group. ASA +/+ mice were examined at 1.8, 4.9,
8.8, 13.0, 16.3, 17.2 and 23.1 months of age with 1-4
animals in each group.
Lipids
Lysosulfatide and glucosylsphingosine used as calibrators
were produced and characterized at the Neurochemistry
laboratory, Mölndal, Sweden [20]. The structure of
synthesized lysosphingolipids was confirmed with
electrospray ionization-mass spectrometry (quadrupole-
time-of-flight, Micromass, Manchester, UK). Radiolabel-
ling of lysosulfatide was performed according to the
method by Schwarzmann et al [21].
Lipid extraction and separation
Frozen brains were mortared under liquid nitrogen and
approximately 100 mg of the homogenized brain powder
was taken for lipid extraction with chloroform:methanol:
water, (C/M/W 4:8:3, by vol . )[ 2 2 ] .F r o mt h el i p i d
extract, an aliquot corresponding to approximately
10 mg (1/10) homogenized brain powder was evapo-
rated and resolved in 5 mL methanol/1M KOH (9/1 by
vol,). Saponification was performed at 37°C for 2 h after
which 5 mL water was added.
The brain extracts were further purified on LCR-C18
columns (Varian Inc, Palo Alto, CA, USA). The LCR-C18
column was activated and washed with 10 bed volumes
of methanol and C/M (1:2 by vol.) respectively, followed
by 20 bed volumes of methanol and water, respectively.
The sample was applied to the column and subsequently
80 bed volumes of water. Lysosulfatide was eluted with
20 bed volumes of M/W (62/38 by vol.) and an internal
standard (glucosylsphingosine, 300 pmol) was then added
to each sample. The sample was evaporated, resolved in
100 μL methanol and derivatized as described below.
The recovery of lysosulfatide was determined by add-
ing
3H-lysosulfatide (corresponding to 830 Bq) to the
lipid extract from brain tissue, as described above. The
amount of
3H-lysosulfatide in the “lysosulfatide fraction”
eluted from the LCR-C18 column was determined by
scintillation counting (Perkin Elmer Tri-Carb 2800 TR,
MA, US) and the recovery was 50% throughout the
whole procedure (triplicates, data not shown).
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Figure 1 Sulfatide (A) and lysosulfatide (B) structures.T h e
glycosphingolipid sulfatide (galactosylceramide-3-O-sulfate) consists
of a ceramide backbone (i.e. a long-chain base and a fatty acid
chain) and a sulfated galactose moiety. Lysosulfatide is the
deacylated form of sulfatide (sulfogalactosylsphingosine).
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Calibrators for lysosulfatide quantification were prepared
from stock solutions (1 nmol/50 μL methanol) and
amounts of 10, 25, 50, 100, 250, 500 and 1000 pmol
were used. The internal calibrator glucosylsphingosine
(300 pmol) was added to each standard. The volume
was corrected to 100 μL by adding methanol to each
standard. Calibrators were N-derivatized with 40 μL
O-phthalaldehyde-(OPA) (Pierce, Illinois, US) for
15 minutes at RT. The detection limit for lysosulfatide
was approximately 2 pmol.
Quantification of lysosulfatide
Lysosulfatide and glucosylsphingosine were N-deriva-
tized with 40 μL OPA (Pierce) for 15 minutes at RT.
Chromatography was performed by the HPLC Varian
9010 system, fitted with a Genesis C18 column (4 μm,
150 × 3 mm, Jones Chromatography, UK). The mobile
phase was methanol-35 mM phosphoric acid in water
(835:165 by vol.) with a flow rate of 1.0 mL min
-1.
A JASCO 821-FP spectrofluorometer with excitation at
335 nm and emission at 420 nm wavelengths was used
for peak detection. Data were collected by PE NELSON
chromatography software (Perkin Elmer Inc., MA, US).
Evaluation
The amount of lysosulfatide in the samples was calcu-
lated using the respective standard curve, as described
above. The quota of lysosulfatide/glucosylsphingosine
(pmol) was calculated for each sample and multiplied by
2 for correction of the 50% recovery of lysosulfatide
throughout the whole procedure. Values are expressed
as mean ± SD.
Results
Lysosulfatide could be detected in the brain of normal
mice (ASA +/+) from the age of 1.8 months. From the
age of 8.8 months, the lysosulfatide levels remained con-
stant at 1 pmol/mg wet tissue (Figure 2). The lysosulfa-
tide levels in the ASA -/- animals increased with age
and peaked around 18.5 months of age (30 pmol/mg
wet tissue) followed by a slight decline (Figure 2).
Discussion
This investigation shows an accumulation of the lyso-
sphingolipid lysosulfatide in the brain of Arylsulfatase A
deficient mice (ASA -/-), a murine model for the human
disease Metachromatic Leukodystrophy (MLD). This
finding is in agreement with previous studies on post
mortem brain tissues from MLD patients [13,14], where
quantification of lysosulfatide used internal standards in
a similar way as described above. However, one study by
Rosengren et al. is not supportive [23]. The reason for
this contradictory result might be the choice of method
in the study by Rosengren et al., where radioimmunoaf-
finity TLC was used for quantification, or possibly the
quality of the brain tissue.
Since the accumulation of lysosphingolipids has been
observed in many of the sphingolipidoses [2,5-10], it
seems reasonable that these substances might play a
role in the pathogenesis of LSDs. Several studies also
support this role, mainly as cytotoxic compounds. The
most thoroughly investigated lyso-compound is the lyso-
sphingolipid of galactosylceramide, psychosine, which
accumulates in Krabbe disease [1,2,24]. The accumula-
tion is closely related to the demyelination process and
it is suggested to involve several mechanisms. These
include regulating protein kinase C mediated growth
factor, interfering with IGF-1 signalling, activating phos-
pholipiase A2 and thus producing lysophosphatidylcho-
line-induced apoptosis and activating TDAG8 receptors
resulting in the production of multinuclear globoid cells,
reviewed by [25]. One might assume similar mechan-
isms being involved in the pathogenesis of MLD but
this remains to be investigated. Thus, the observation of
accumulated lysosulfatide in the ASA -/- mouse suggests
this model to be a suitable tool for functional studies of
lysosulfatide in the pathogenesis of MLD.
It must be mentioned that the ASA deficient mouse
does not demyelinate in the central nervous system [18].
In this respect it is interesting to compare the lysosulfa-
tide levels found in patients who develop demyelination.
In the white matter of MLD patients, levels ranging
from 50-200 pmol/mg wet weight of lysosulfatide have
been found [13,14]. These levels are higher than those
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Figure 2 Lysosulfatide accumulates in brain from arylsulfatase
A-deficient mice. Graphs show developmental profiles of
lysosulfatide in ASA -/- mouse brains (squares) and ASA +/+ mouse
brains (circles). Each age group contained 2-4 animals for ASA -/-
mice and 1-4 animals for ASA +/+ mice. The mean value for each
age group was calculated, as well as the corresponding SD. Error
bars represents the SD of the mean.
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concentrations of lysosulfatide were found to be similar
when comparing human control cerebral white matter
with the brain of ASA +/+ mice. Thus, if lysosulfatide is
indeed a major cause of demyelination in MLD the
comparatively low levels found in ASA -/- mice would
explain the lack of demyelination in this animal model.
Lipid rafts, enriched in cholesterol and sphingolipids,
act as scaffolds on which different signalling molecule
assemble [26]. These domains play a central role in
many cellular processes including membrane sorting
and trafficking, signal transduction, cell growth and sur-
vival. The list of various diseases where raft formation
plays an important role in disease progression continues
to grow [27] and includes the possibility of these
domains being involved at a cellular level in the patho-
genesis of LSDs. White et al. recently showed an accu-
mulation of psychosine in rafts isolated from the post
mortem brain of human Krabbe patients and from brain
and sciatic nerve of the twitcher mouse [28]. Psychosine
accumulation was accompanied by increased levels of
cholesterol in these domains and changes in the distri-
bution of the raft markers flotilin-1 and caveolin-1.
Furthermore, these molecular changes were associated
with the inhibitory effect of psychosine on protein
kinase C. The authors propose a model of psychosine
involvement in raft-modulated cell functions by disrupt-
ing the raft architecture and deregulating signal activity
(disorganisation of myelin components, inflammation,
synaptic dysfunction, axonal defects). Since the ethiology
of MLD is somewhat similar to Krabbe disease, it is rea-
sonable to assume that raft disruption involving lysosul-
fatide accumulation might play a role in disease
progression. However, the accumulation of lysosulfatide
in rafts of MLD patients and ASA mice remains to be
investigated.
Conclusion
In agreement with the accumulation of lysosulfatide in
the brain of patients with metachromatic leukodystro-
phy, ASA null mutant mice also showed increased
a m o u n t so ft h i sl y s o s p h i n g o lipid in the brain. Further-
more, a developmental increase of lysosulfatide was
observed. Lysosulfatide is considered to be a possible
pathogenic agent in MLD contributing to the severe
demyelination occurring in these patients. However, the
mechanism of involvement is not known. The ASA null
mutant mice might be a suitable model to investigate
t h er o l eo fl y s o s u l f a t i d ei nt h ep a t h o g e n e s i so fM L D ,
including the peripheral demyelination of these animals.
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